By using in vitro studies, we show that the F276C FGFR2 variant is sensitive to BGJ398, a pan-FGFR inhibitor, which was also reflected clinically in the response of a patient’s tumor when treated with BGJ398 as part of a clinical trial (Fig 5). The gene discussed is FGFR2; the disease is neoplasm.